Docetaxel,Cisplatin versus Carboplatin,weekly Paclitaxel for patients with advanced non-small cell lung cancer : a prospective randomized phase II study of the Niigata Lung Cancer Treatment Group

INTERVENTION: Treatment group A: DOC 45mg/m2 day1,15 CDDP 40mg/m2 day1,15 Treatment group B: PTX 70mg/m2 day1,8,15 CBDCA AUC = 6 day1 CONDITION: Non‐small cell lung cancer PRIMARY OUTCOME: Response rate, survival SECONDARY OUTCOME: Progression free survival,safety, toxicity, QOL INCLUSION CRITERIA: Patients enrolled in this trial had histologically or cytologically confirmed NSCLC who are in‐operable or not candidates for thoracic radiation, if they had not received previous chemotherapy, had measurable disease, and had a life expectancy of at least 3 months. Additional entry criteria were age 20=< years, performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale, and adequate bone marrow (leukocyte count > 4,000/mm3, <12,000/mm3, neutrophil count>2,000/mm3, hemoglobin concentration > 9.5g/dL, platelet count > 100,000/mm3), kidney (creatinine < 1.2 mg/dL), liver (aspartate aminotransferase[AST] and alanine aminotransferase [ALT] < 100, total bilirubin < 2.0 mg/dL), and pulmonary (PaO2 > 60 torr) functions.